A Rare Presentation of Porphyria Cutanea Tarda in a Patient With Treated Hepatitis C: A Case Report and Review of Management Constraints
Shamas Rafique, Iqra Rafiq
Researchers' Journal of Internal Medicine.
Introduction: Porphyria cutanea tarda (PCT) is the most common disorder of porphyrin metabolism, resulting from a deficiency of uroporphyrinogen decarboxylase (UROD). It manifests with blistering cutaneous lesions on sun-exposed skin and is strongly associated with hepatitis C virus (HCV) infection. Case Presentation: A 70-year-old Asian male with a history of successfully treated Hepatitis C presented with a several-month history of severe pruritus, skin fragility, blistering, and hyperpigmentation on sun-exposed areas. Diagnosis was supported by urinary porphyrin fractionation showing a classic pattern alongside elevated porphobilinogen (10.6 mg/24h) and delta-aminolevulinic acid (17.8 mg/24h) in the context of unequivocal clinical findings. Treatment and Outcome: The patient was initiated on low-dose hydroxychloroquine (125 mg orally twice weekly). At six-week and three-month follow-ups, he reported a marked reduction in pruritus, complete cessation of new blister formation, and significant improvement in skin integrity. Conclusion: This case underscores that PCT can manifest years after successful HCV treatment and highlights a pragmatic, cost-conscious diagnostic approach. Low-dose hydroxychloroquine proved to be a safe and highly effective therapy, leading to rapid and sustained clinical improvement.